Bumgardner G L, Li J, Prologo J D, Heininger M, Orosz C G
Department of Surgery, The Ohio State University and Medical Center, Columbus 43210, USA.
Transplantation. 1999 Aug 27;68(4):555-62. doi: 10.1097/00007890-199908270-00019.
This is the first in a series of reports that characterizes immune responses evoked by allogeneic hepatocytes using a functional model of hepatocyte transplantation in mice.
"Donor" hepatocytes expressing the transgene human alpha-1-antitrypsin (hA1AT-FVB/N, H2q) were transplanted into C57BL/6 (H2b) or MHC II knockout (H2b) hosts treated with anti-CD4, anti-CD8, or a combination of anti-CD4 and anti-CD8 monoclonal antibodies (mAbs). Hepatocyte rejection was determined as a loss of circulating ELISA-detectable transgene product (hA1AT). In addition, some C57BL/6 mice underwent transplantation with FVB/N heterotopic cardiac allografts and were treated with anti-CD4 mAb. Cardiac allograft rejection was determined by palpation. Graft recipients were tested for donor-reactive alloantibodies and donor-reactive delayed-type hypersensitivity (DTH) responses.
The median survival time (MST) of allogeneic hepatocytes in normal C57BL/6 mice was 10 days (no treatment), 10 days (anti-CD4 mAb), 14 days (anti-CD8 mAb), and 35 days (anti-CD4 and anti-CD8 mAbs). The MST of hepatocytes in B6 MHC class II knockout mice was 10 days (no treatment) and 21 days (anti-CD8 mAb). The MST of cardiac allografts was 11 days (no treatment) and >100 days (anti-CD4 mAb). Donor-reactive DTH responses were readily detected in both untreated and mAb-treated recipients. Donor-reactive alloantibody was barely detectable in untreated hosts.
These studies demonstrate that allogeneic hepatocytes are highly immunogenic and stimulate strong cell-mediated immune responses by both CD4+ and CD8+ T cells, even when treated with agents that can cause acceptance of cardiac allografts. Indeed, CD4+ or CD8+ T cells seem to independently cause hepatocellular allograft rejection. Allogeneic hepatocytes evoked strong donor-reactive DTH responses but were poor stimuli for donor-reactive antibody production. This is an unusual pattern of immune reactivity in allograft recipients.
这是一系列报告中的第一篇,该系列报告使用小鼠肝细胞移植功能模型来描述同种异体肝细胞引发的免疫反应。
将表达转基因人α-1-抗胰蛋白酶(hA1AT-FVB/N,H2q)的“供体”肝细胞移植到用抗CD4、抗CD8或抗CD4与抗CD8单克隆抗体(mAb)联合处理的C57BL/6(H2b)或MHC II基因敲除(H2b)宿主中。肝细胞排斥反应通过循环中ELISA可检测的转基因产物(hA1AT)的丧失来确定。此外,一些C57BL/6小鼠接受了FVB/N异位心脏同种异体移植,并接受抗CD4 mAb治疗。通过触诊确定心脏同种异体移植排斥反应。对移植受体进行供体反应性同种异体抗体和供体反应性迟发型超敏反应(DTH)检测。
同种异体肝细胞在正常C57BL/6小鼠中的中位生存时间(MST)为10天(未治疗)、10天(抗CD4 mAb)、14天(抗CD8 mAb)和35天(抗CD4和抗CD8 mAb)。B6 MHC II类基因敲除小鼠中肝细胞的MST为10天(未治疗)和21天(抗CD8 mAb)。心脏同种异体移植的MST为11天(未治疗)和>100天(抗CD4 mAb)。在未治疗和mAb治疗的受体中均易于检测到供体反应性DTH反应。在未治疗的宿主中几乎检测不到供体反应性同种异体抗体。
这些研究表明,同种异体肝细胞具有高度免疫原性,即使在用可导致心脏同种异体移植接受的药物处理时,也能刺激CD4+和CD8+ T细胞产生强烈的细胞介导免疫反应。实际上,CD4+或CD8+ T细胞似乎独立导致肝细胞同种异体移植排斥。同种异体肝细胞引发强烈的供体反应性DTH反应,但对供体反应性抗体产生的刺激较弱。这是同种异体移植受体中一种不寻常的免疫反应模式。